These include some antigens such as signaling lymphocyte activation molecule family-7 (SLAMF-7) (expression in 95% MM), CD138 (expression in 90–100% MM), CD38 (expression in 80–100% MM), CD56 (expression in 70–90% MM), Kappa (κ) light chain (expression in 35% MM) as well as overexpressed antigens like natural-killer group 2 member D (NKG2D), G protein-coupled receptor class C group 5 member D (GPRC5D), integrin‐Beta7, MMG49, CD44v6, CD74, NY-ESO-1, TnMUC1, APRIL, TACI and CD19 [71, 80] (Table 2). This evidence concerns the gene CD19 and Miyoshi myopathy.